For the additional vaccination phase

Size: px
Start display at page:

Download "For the additional vaccination phase"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: (HAB-138 Ext: 028 Y11), (HAB-139 Ext: 028 Y12), (HAB-140 Ext: 028 Y13), (HAB-141 Ext: 028 Y14), (HAB-142 Ext: 028 Y15) Title: A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals combined hepatitis A - hepatitis B vaccine when administered in healthy adults. Twinrix (HAB): GlaxoSmithKline (GSK) Biologicals combined hepatitis A and hepatitis B vaccine. Havrix (HAV): GSK Biologicals hepatitis A vaccine. Engerix (HBV): GSK Biologicals hepatitis B vaccine. Rationale: The aim of the long-term follow-up (LTFU) study was to evaluate the long-term persistence of humoral immune response from Year 11 to Year 15 after administration of the first dose of HAB vaccine [Study /021 (HAB-028), primary vaccination]. The safety of the study vaccine was also assessed. The summary presents results for the LTFU period at Years 11, 12, 13, 14 and 15. Please refer to the HAB-028 CTRS for results on the primary study and to the /115 & 119 CTRS for results on Months 108 & 120 (Years 9 and 10). Phase: III Study Period: LTFU at Year 11 (HAB-138): 24 November 2004 to 20 December 2004 LTFU at Year 12 (HAB-139): 16 November 2005 to 12 December 2005 LTFU at Year 13 (HAB-140): 10 November 2006 to 11 December 2006 LTFU at Year 14 (HAB-141): 27 September 2007 to 20 December 2007 LTFU at Year 15 (HAB-142): 21 October 2008 to 07 December 2009 Study Design: The long-term follow-up studies were open and self-contained. Centres: Single study centre in Belgium. Indication: Protection of healthy adults between 17 and 39 years of age, against hepatitis A and hepatitis B infection. Treatment: During the primary study (208127/021), the subjects received 3 doses of HAB vaccine (Lot 1, Lot 2 or Lot 3) according to a 0, 1, 6 month schedule. For the data analyses in the LTFU phase, the 3 groups were pooled. If a subject became seronegative for anti-hav (antibodies to hepatitis A virus) antibodies (i.e. concentrations < 15 miu/ml) or lost seroprotective concentrations for anti-hbs (antibodies to hepatitis B surface antigen) antibodies (i.e. concentrations < 10 miu/ml) at any of the long-term blood sampling time points (i.e. Years 11, 12, 13, 14 or 15), he/ she was offered an additional vaccine dose of HAB, HAV or HBV vaccine (administered between 6 to 12 months after the Year 15 time point). This was done in order to assess the immune memory after a primary three-dose schedule of HAB vaccine. The additional vaccine was administered intramuscularly into the deltoid region of the non-dominant arm. Objectives: For the long-term follow-up phase To evaluate anti-hav and anti-hbs antibody persistence at Years 11, 12, 13, 14 and 15 after the first vaccine dose of three-dose primary vaccination. For the additional vaccination phase To evaluate the immune memory 15 years after primary vaccination (with a three-dose vaccination schedule of HAB vaccine) in subjects who became seronegative for anti-hav antibodies (i.e. titres < 15 miu/ml) or lost seroprotective titres for anti-hbs antibodies (i.e. titres < 10 miu/ml) at the long-term blood sampling time point (i.e. Years 11, 12, 13, 14 or 15) and who received additional vaccine dose (administered between 6 to 12 months after the Year 15 time point). Primary Outcome/Efficacy Variable: For the long-term follow-up phase (at Years 11,12, 13, 14 and 15) Antibody persistence against the study vaccine antigens : - Anti-HAV: percentage of seropositive subjects and geometric mean concentrations (GMCs). - Anti-HBs: percentage of seropositive subjects, subjects with anti-hbs concentrations 10 miu/ml and GMCs. For the additional vaccination phase Immune response to the study vaccine antigen, before and one month after the additional vaccination: - Anti-HAV antibody concentrations (after an additional dose with HAV vaccine*). - Anti-HBs antibody concentrations (after an additional dose with HBV vaccine).

2 Anamnestic response to the additional vaccination. Anamnestic response for anti-hav antibody was defined as: - Anti-HAV antibody concentrations 15 miu/ml at one month post-additional vaccination in subjects, seronegative at the pre-additional vaccination time point. - At least a 2-fold increase in anti-hav antibody concentrations one month after the additional vaccination, in subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point. - At least a 4-fold increase in anti-hav antibody concentration one month after the additional vaccination, in seropositive subjects having anti-hav antibody concentrations < 100 miu/ml at the pre-additional vaccination time point. Anamnestic response for anti-hbs antibody was defined as: - Anti-HBs antibody concentrations 10 miu/ml at one month post-additional vaccination in subjects seronegative at the pre-additional vaccination time point. - At least a 4-fold increase in anti-hbs antibody concentrations, at one month post-additional vaccination in subjects seropositive at the pre-additional vaccination time point. Serious adverse events (SAEs): - SAEs which the subject experienced since the previous study visit were to be documented only if the SAE was assessed by the investigator to have a causal relationship to primary vaccination. SAEs related to study participation (blood sampling) and any event related to a lack of vaccine efficacy (i.e. hepatitis A infection or hepatitis B infection) were also to be documented. - Occurrence, intensity and relationship to vaccination of all SAEs following the administration of the additional vaccine dose. Outcome variables were not differentiated into primary and secondary in the study protocol, hence all outcome variables were considered as primary outcome variables. Secondary Outcome/Efficacy Variable:. Statistical Methods: The analyses were conducted on the Long-Term (LT) Total Vaccinated Cohort and the LT According-To-Protocol (LT-ATP) cohort for immunogenicity. The LT Total Vaccinated Cohort included all subjects (i.e. subjects who had received at least one dose of the study vaccine in the primary study) who returned for blood sampling at the particular long-term blood sampling time point (Year 11,12, 13, 14 or 15) and for whom serology results were available for anti-hav and/ or anti-hbs antibodies. The LT-ATP cohort for immunogenicity included subjects who returned at a particular blood sampling time point, the LT-ATP immunogenicity cohort (at that time point) included subjects who were included in the ATP immunogenicity cohort in the primary study, for whom serology results were available for that particular blood sampling time point and who were not eliminated either for vaccine administration forbidden in study protocol or for abnormal increase in anti-hav and/ or anti-hbs antibody titres, during the long-term follow-up. The definition of abnormal increase depended on the magnitude of the concentration at the previous time point (reference value). Abnormal increase in antibody concentrations was defined as a two-fold increase or more in antibody concentrations (when the antibody concentration at the reference time point was 100 miu/ml) or a four-fold increase or more in antibody concentrations (when the antibody concentration at the reference time point was < 100 miu/ml). Analysis of immunogenicity: The analysis of immunogenicity was performed on the LT-ATP cohort for immunogenicity. During the primary study, lot-to-lot consistency was demonstrated; therefore the analyses for the LT follow-up were presented for the. At each yearly blood sampling time point, anti-hav & anti-hbs seropositivity* rates and GMCs with their 95% confidence interval (CI) were tabulated; seroprotection** rates for anti-hbs with 95% CI were tabulated. Note: A decrease in the specificity of the anti-hb ELISA assay had been observed in some studies for low levels of antibody ( miu/ml). The table shows updated results following complete retesting and reanalysis. *Seropositivity: for HAV antibodies was defined as antibody concentrations 15 miu/ml. for anti-hbs antibodies was defined as antibody concentrations 3.3 miu/ml for the in-house ELISA and 6.2 miu/ml for the ChemiLuminescence ImmunoAssay (CLIA). **Seroprotection for anti-hbs antibodies was defined as antibody concentrations 10 miu/ml. For subjects who received the additional vaccine dose between 6 to 12 months after Year 15 time point, the immunogenicity response was also tabulated.

3 Analysis of safety: The analysis of safety was performed on the LT Total Vaccinated Cohort. The occurrence of any SAE which the subject could have experienced since the last study visit was reported if the SAE was assessed by the investigator to have a causal relationship to primary vaccination; SAEs related to study participation (blood sampling) were tabulated. Finally, lack of vaccine efficacy (i.e. hepatitis A or hepatitis B infection) was also reported as SAE. For the additional vaccine dose: For subjects who received the additional vaccine dose between 6 to 12 months after Year 15 time point, the safety results were summarized. Study Population: Healthy male and female subjects between the ages of 17 and 39 years, seronegative for anti-hav, anti-hbs, anti-hepatitis B core antigen (anti-hbc) antibodies and/or hepatitis B surface antigen (HBsAg) at the time of first dose of primary vaccination. Written informed consent was obtained before each blood sampling visit of the LTFU study. Year 11 time point Number of subjects Planned, N Entered, N (LT Total Vaccinated Cohort) 37 Completed, n (%) 37 (100) Total Number Subjects Withdrawn, n (%) 0 (0.0) Withdrawn for other reasons, n (%) 0 (0.0) N (LT Total Vaccinated Cohort) 37 Females: Males 27:10 Mean Age, years (SD) 30.4 (3.08) White/Caucasian, n (%) 37(100) Year 12 time point Number of subjects Planned, N 40 Randomised, N (LT Total Vaccinated Cohort) Completed, n (%) 40 (100) Total Number Subjects Withdrawn, n (%) 0 (0.0) Withdrawn for other reasons, n (%) 0 (0.0) N (LT Total Vaccinated Cohort) 40 Females: Males 29:11 Mean Age, years (SD) 31.4 (2.95) White/Caucasian, n (%) 40 (100) Year 13 time point Number of subjects Planned, N 37 Randomised, N (LT Total Vaccinated Cohort) Completed, n (%) 37 (100) Total Number Subjects Withdrawn, n (%) 0 (0.0) Withdrawn for other reasons, n (%) 0 (0.0) N (LT Total Vaccinated Cohort) 37 Females: Males 28:9 Mean Age, years (SD) 31.9 (1.13) White/Caucasian 37 (100) Year 14 time point

4 Number of subjects Planned, N 43 Randomised, N (LT Total Vaccinated Cohort) Completed, n (%) 43 (100) Total Number Subjects Withdrawn, n (%) 0 (0.0) Withdrawn for other reasons, n (%) 0 (0.0) N (LT Total Vaccinated Cohort) 43 Females: Males 35:8 Mean Age, years (SD) 33.0 (1.42) White/Caucasian, n (%) 42 (97.7) Year 15 time point Number of subjects Planned*, N 50 Randomised, N (LT Total Vaccinated Cohort) Completed, n (%) 49 (98.0) Total Number Subjects Withdrawn, n (%) 1 (2.0) Withdrawn for other reasons, n (%) 1 (2.0) N (LT Total Vaccinated Cohort) 50 Females: Males 39:11 Mean Age, years (SD) 34.4 (2.66) White/Caucasian, n (%) 48 (96.0) Primary Efficacy Results: Seropositivity rates and GMCs (calculated on seropositive subjects) of anti-hav antibodies (LT ATP cohort for immunogenicity) Group Timing N S+ GMC (miu/ml) n % 95% CI Value 95% CI LL UL LL UL Pooled PIII(M7) PIII(M18) PIII(Year 2) PIII(Year 3) PIII(Year 4) PIII(Year 5) PIII(Year 6) PIII(Year 6)* PIII(Year 7) PIII(Year 8) PIII(Year 9) PIII(Year 10) PIII(Year 11) PIII(Year 12) PIII(Year 13) PIII(Year 14) PIII(Year 15)** * There was a change of assay kit at Year 7 time point, thus for the sake of bridging, blood samples corresponding to Year 6 were re-tested with the new assay kit. **At Year 15, the ATP cohort was revised due to change in the elimination code based on CLIA N = number of subjects with available results

5 GMC = geometric mean concentrations calculated on seropositive subjects S+ = seropositivity for anti-hav antibodies defined as: antibody concentrations 33 miu/ml for time points PIII (M7) to PIII(Year 6) antibody concentrations 15 miu/ml for time points PIII (Year 6) to PIII(Year 15) (these cut-off values differ because of a change in assay kit) n (%) = number (percentage) of subjects with antibody concentration within the specified range 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PIII(Mx) = blood sampling after Dose 3, at Month x after first vaccine dose at primary study PIII(Year x) = blood sampling after Dose 3, at Year x after first vaccine dose at primary study Primary Efficacy Results: Seropositivity, seroprotection rates and GMCs, (calculated on seropositive subjects) of anti-hbs antibodies (LT ATP cohort for immunogenicity) # Group Timing N S+ 10 miu/ml GMC (miu/ml) n % 95% CI n % 95% CI Value 95% CI LL UL LL UL LL UL Pooled PIII(M7) PIII(M18) PIII(Year 2) PIII(Year 3) PIII(Year 4) PIII(Year 5) PIII(Year 6) PIII(Year 6)* PIII(Year 7) PIII(Year 8) PIII(Year 9) PIII(Year 10) PIII(Year 11) PIII(Year 12) PIII(Year 13)** PIII(Year 14) PIII(Year 14) $ PIII(Year 15) * There was a change of assay kit at Year 7 time point, thus for the sake of bridging, blood samples corresponding to Year 6 were re-tested with the new assay kit. **From Year 13 to Year 14, anti-hbs antibody concentrations were tested with the in-house ELISA with cut-off 3.3 miu/ml $ There was a change of assay kit at Year 15 time-point, thus for the sake of bridging, blood samples corresponding to Year 14 were also re-tested with CLIA. S+ = Seropositivity for anti-hbs antibodies defined as : antibody concentrations 1.0 miu/ml for time points PIII (M7) to PIII(Year 6) antibody concentrations 3.3 miu/mlfor time points PIII(Year 6) to PIII(Year 14) antibody concentrations 6.2 miu/ml for time points PIII(Year 14 $ ) and PIII(Year 15) (these cut-off values differ because of a change in assay kit) N = number of subjects with available results n (%) = number (percentage) of subjects with antibody concentration within the specified range GMC = geometric mean concentrations calculated on seropositive subjects 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PIII(Mx) = blood sampling after Dose 3, at Month x after first vaccine dose at primary study PIII(Year x) = blood sampling after Dose 3, at Year x after first vaccine dose in primary study # A decrease in the specificity of the anti-hb ELISA assay had been observed in some studies for low levels of antibody ( miu/ml). The table shows updated results following complete retesting and reanalysis. Primary Efficacy Results: Anti-HBs antibody concentrations before and one month for subjects* who received an additional vaccine dose of HBV (LT Total vaccinated Cohort)

6 Time point determining eligibility Anti-HBs (miu/ml) at time point determining eligibility (Year 11) Anti-HBs (miu/ml) preadditional vaccine dose Anti-HBs (miu/ml) at Day 30 post-additional vaccine dose Anamnestic response** Year 11 <3.3 < Yes Year 11 < Yes *2 subjects received additional vaccine dose **anamnestic response for anti-hbs antibody is defined as - Anti-HBs antibody concentrations 10 miu/ml at one month post-additional dose in subjects seronegative at the pre-additional vaccination time-point. - At least a 4-fold increase in anti-hbs antibody concentrations, at one month post-additional dose in subjects seropositive at the pre-additional vaccination time-point. Primary Efficacy Results: Number (%) of subjects reporting solicited local symptoms during the 4-day (Days 0-3) postvaccination period (LT Total Vaccinated Cohort) Symptom Intensity N n % 95 % CI LL UL Pain Any Grade Redness Any >20 mm Swelling Any >20 mm N = Number of subjects with the administered dose n (%) = Number (percentage) of subjects reporting at least once the symptom 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = Incidence of a local symptom regardless of grade or relationship to vaccination Grade 3 pain = Symptom that prevented normal everyday activities Primary Efficacy Results: Number (%) of subjects reporting solicited general symptoms during the 4-day (Days 0-3) post-vaccination period (LT Total Vaccinated Cohort) Symptom Intensity/Relationship N n % 95 % CI LL UL Fatigue Any Grade Related Fever/(Axillary) 37.5 C >39.0 C Related Gastrointestinal Any Grade Related Headache Any Grade Related N = Number of subjects with the administered dose n (%) = Number (percentage) of subjects reporting at least once the symptom 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = Incidence of a general symptom irrespective of intensity grade or relationship to vaccinations Grade 3 = Symptom which prevented normal everyday activities Related = Symptom assessed by the investigator as causally related to study vaccination. Secondary Outcome variable(s):. Safety Results: Number (%) of subjects who received an additional vaccine dose after Year 15, with unsolicited adverse events (LT Total Vaccinated Cohort) Most frequent adverse events occurring during the 30-

7 day follow-up vaccination period after vaccination N=2 Subjects with any AE(s), n (%) 1 (50.0) Subjects with grade 3 AE(s), n (%) 0 (0.0) Subjects with related AE(s), n (%) 1 (50.0) Heaviness sensation above eyes 1 (50.0) procedures, or lack of vaccine efficacy, reported up to Year 11 (LT Total Vaccinated Cohort) N = 37 N = 37 procedures, or lack of vaccine efficacy, reported up to Year 12 (LT Total Vaccinated Cohort) N = 40 N = 40 procedures, or lack of vaccine efficacy, reported up to Year 13 (LT Total Vaccinated Cohort) N = 37 N = 37 procedures, or lack of vaccine efficacy, reported up to Year 14 (LT Total Vaccinated Cohort) N = 43 N = 43 procedures, or lack of vaccine efficacy, reported up to Year 15 (LT Total Vaccinated Cohort) N = 50 N = 50 Safety Results: Number (%) of subjects with serious adverse events occurring during the 30-day follow-up period after the additional vaccination dose (LT Total Vaccinated Cohort) N = 2

8 N = 2 Conclusion: From Year 11 to Year 15, all subjects had anti-hav antibody concentrations 15mIU/mL; at the same time points the GMC for anti-hav antibody was at least Further, at least 87.0% of subjects had anti-hbs antibody concentrations 10 miu/ml from Year 11 to Year 15; the GMC for anti-hbs antibody was at least Two subjects received an additional vaccine dose of HBV vaccine and showed an anamnestic response to the additional vaccination. No solicited local symptoms were reported and solicited general symptoms (fatigue and gastrointestinal symptoms) were reported by 2 subjects during the 4-day (Days 0-3) follow up period after the additional vaccine dose. Unsolicited adverse event was reported by 1 of the 2 subjects with the additional dose of the vaccine. No SAEs related to the primary vaccination or to the study procedures were reported during the LT follow-up studies up to Year 15. The publications listed below describe results for the primary study and the Long-Term Persistence study up to Month 120. Date updated: 20-March-2014

subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.

subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Long-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008

Long-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Synopsis of study HBV-314 BST 280 (108988)

Synopsis of study HBV-314 BST 280 (108988) Synopsis of study HBV-314 BST 280 (108988) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full

More information

Synopsis for study HAV-112 EXT M210 (110678)

Synopsis for study HAV-112 EXT M210 (110678) Synopsis for study HAV-112 EXT M210 (110678) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Analysis of immunogenicity

Analysis of immunogenicity The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Study No.: Title: Rationale:  Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

To demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered

To demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

vaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.

vaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

MenC. MenW MenY

MenC. MenW MenY The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group

Study No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

D-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming

D-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before approval of AMBIRIX. This scientific discussion has

More information

Analysis of safety The analysis was performed on the Total Vaccinated cohort.

Analysis of safety The analysis was performed on the Total Vaccinated cohort. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of TWINRIX Paediatric. This scientific discussion has been updated until 01 February 2004. For information

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand

Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand http://waipra.blogspot.com/2011/02/9.html Burden of disease in Thailand Liver diseases

More information

TABULAR FORMAT REFERRING TO PART OF THE DOSSIER Volume: Page:

TABULAR FORMAT REFERRING TO PART OF THE DOSSIER Volume: Page: Title of the study : A phase III, multicentric open study to evaluate the immunological memory induced by a 3-dose primary vaccination followed by a booster dose with GSK Biologicals 11-valent conjugate

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

vaccination in Canada Bernard Duval, md, mph, frcpc Institut National de Santé Publique du Québec Québec, Canada Sevilla,

vaccination in Canada Bernard Duval, md, mph, frcpc Institut National de Santé Publique du Québec Québec, Canada Sevilla, Follow-up of hepatitis B vaccination in Canada Bernard Duval, md, mph, frcpc Institut National de Santé Publique du Québec Québec, Canada Sevilla, 2004-03 03-11 HB in Canada Low endemicity: HBsAg+ : 0.5%

More information

Acombination vaccine including diphtheria,

Acombination vaccine including diphtheria, Immunogenicity and Safety of Combined Diphtheria-Tetanus-Whole cell Pertussis- Hepatitis B/ Haemophilus Influenzae Type b Vaccine in Indian Infants S.B. Bavdekar*, P.P. Maiya*, S.D. Subba Rao, S.K. Datta**

More information

Twinrix Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed)

Twinrix Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed) Twinrix Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed) QUALITATIVE AND QUANTITATIVE COMPOSITION Suspension for injection. One dose (1.0 ml) contains: Hepatitis A virus (inactivated) 1,2

More information

GSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:

GSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed) 720 ELISA Units Hepatitis B surface antigen 3,4

Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed) 720 ELISA Units Hepatitis B surface antigen 3,4 Twinrix TM 1. NAME OF THE MEDICINAL PRODUCT Twinrix TM Inactivated hepatitis A and rdna hepatitis B vaccine (adsorbed) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Suspension for injection. One dose (1.0ml)

More information

AUSTRALIAN PRODUCT INFORMATION. ENGERIX-B (hepatitis B surface antigen recombinant (yeast)) vaccine, suspension for injection

AUSTRALIAN PRODUCT INFORMATION. ENGERIX-B (hepatitis B surface antigen recombinant (yeast)) vaccine, suspension for injection AUSTRALIAN PRODUCT INFORMATION ENGERIX-B (hepatitis B surface antigen recombinant (yeast)) vaccine, suspension for injection 1 NAME OF THE MEDICINE Hepatitis B surface antigen recombinant (yeast) 2 QUALITATIVE

More information

GSK Cervical Cancer Vaccine:

GSK Cervical Cancer Vaccine: GSK Cervical Cancer Vaccine: Overview of Clinical Data Jovelle B. Laoag-Fernandez, M.D., Ph.D., FPOGS Regional Medical Affairs HPV Vaccines GSK Biologicals Asia Pacific, Australasia, China/Hong Kong, Japan

More information

Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended

Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended < Typhim Vi > AT/W/0017/pdWS/001-002 Marketing

More information

Selected Primary-Care Issues in HIV Disease

Selected Primary-Care Issues in HIV Disease Perspective Selected Primary-Care Issues in HIV Disease Primary care for HIV-infected patients includes ensuring that eligible patients receive hepatitis B and A virus vaccinations, all women undergo appropriate

More information

Immunogenicity and Safety of GSK s FluLaval Quadrivalent Inactivated Influenza Vaccine in Children 6-35 Months of Age

Immunogenicity and Safety of GSK s FluLaval Quadrivalent Inactivated Influenza Vaccine in Children 6-35 Months of Age Immunogenicity and Safety of GSK s FluLaval Quadrivalent Inactivated Influenza Vaccine in Children 6-35 Months of Age Bruce L Innis, MD, FIDSA GSK Vaccines Inactivated Influenza Vaccines for 6-35 Months

More information

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011 Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Thu, 17 Jan 2019 04:33:43 GMT) CTRI Number Last Modified On 26/06/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. Name of Sponsor/ Company: Sanofi Pasteur Study Code: Study Identifier:

More information

Novartis Vaccines and Diagnostics S.r.l

Novartis Vaccines and Diagnostics S.r.l 28 OCT 15 Page 1 of 11 Sponsor: Investigational Product: Indication: Protocol Number: Protocol Title: Phase of Development: and Diagnostics S.r.l ativ (Adjuvanted trivalent influenza virus vaccine (surface

More information

Rapporteur: Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended

Rapporteur: Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Rapporteur s Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended DE/W/0054/pdWS/002-005 Marketing Authorisation Holder: GlaxoSmithKline

More information

TRANSPARENCY COMMITTEE OPINION. 19 May 2010

TRANSPARENCY COMMITTEE OPINION. 19 May 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 May 2010 HAVRIX 1440 U/1 ml ADULTES, suspension for injection in prefilled syringe. Hepatitis A virus (inactivated,

More information

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

TWINRIX (720/20) and TWINRIX JUNIOR (360/10) PRODUCT INFORMATION (Combined Hepatitis A and Hepatitis B vaccine)

TWINRIX (720/20) and TWINRIX JUNIOR (360/10) PRODUCT INFORMATION (Combined Hepatitis A and Hepatitis B vaccine) 1 TWINRIX (720/20) and TWINRIX JUNIOR (360/10) PRODUCT INFORMATION (Combined Hepatitis A and Hepatitis B vaccine) NAME OF THE MEDICINE TWINRIX combined hepatitis A and hepatitis B vaccine DESCRIPTION TWINRIX

More information

Experience with the first wp based fully liquid hexavalent vaccine.

Experience with the first wp based fully liquid hexavalent vaccine. Experience with the first wp based fully liquid hexavalent vaccine. EasySix TM Vaccine R K Suri Senior Advisor & Former Chief Executive- Biologicals Panacea Biotec Ltd New Delhi, INDIA October 31, 2018

More information

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source: GSK Medicine: Not applicable Study No.: 113564 (EPI-HAV-003 BOD MX) Title: Sero-prevalence of Hepatitis A, Varicella-Zoster virus, Cytomegalovirus, Herpes Simplex and Bordetella pertussis in Mexico. Rationale:

More information

Vaccine 28 (2010) Contents lists available at ScienceDirect. Vaccine. journal homepage:

Vaccine 28 (2010) Contents lists available at ScienceDirect. Vaccine. journal homepage: Vaccine 28 (2010) 730 736 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Persistence of antibodies and immune memory to hepatitis B vaccine 20 years

More information

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended.

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended (Purified Diphtheria Toxoid Purified Tetanus Toxoid Adsorbed purified

More information

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) DESCRIPTION CERVARIX contains recombinant C-terminally truncated L1 proteins from human papillomavirus

More information

TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide)

TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide) TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide) DESCRIPTION TYPHERIX is a colourless, sterile liquid containing the cell surface Vi polysaccharide extracted from Salmonella typhi Ty2

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given

Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given REFERENCES CONTENT ALERTS Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 AS04-Adjuvanted

More information

RESULTS SUMMARY. 45 Poplar Road Parkville, Victoria 3052 Australia. 31 May 2005 (First Participant, First Visit [FPFV]) Not applicable

RESULTS SUMMARY. 45 Poplar Road Parkville, Victoria 3052 Australia. 31 May 2005 (First Participant, First Visit [FPFV]) Not applicable RESULTS SUMMARY A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Influenza Vaccine () in Healthy Adults aged 18 to < 60 years and in Healthy Older Adults aged 60 years for the

More information

Guideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients

Guideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients Guideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients WOMEN AND CHILDREN S DIRECTORATE ACUTE SERVICES DIVISION GUIDELINES TITLE Guideline on

More information

TWINRIX [Hepatitis A & Hepatitis B (Recombinant) Vaccine] Suspension for Intramuscular Injection Initial U.S. Approval: 2001

TWINRIX [Hepatitis A & Hepatitis B (Recombinant) Vaccine] Suspension for Intramuscular Injection Initial U.S. Approval: 2001 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TWINRIX safely and effectively. See full prescribing information for TWINRIX. TWINRIX [Hepatitis

More information

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV Supplemental Digital Content 1. Methodology Inclusion and exclusion criteria Eligible participants were infants between and including 6 10 weeks of age at the time of the first vaccination, who were free

More information

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. Twinrix Adult

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. Twinrix Adult For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Twinrix Adult Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Hepatitis B and Hepatitis B Vaccine

Hepatitis B and Hepatitis B Vaccine Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Sun, 06 Jan 2019 11:39:39 GMT) CTRI Number Last Modified On 15/02/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

ENGERIX -B PRODUCT INFORMATION (Hepatitis B surface antigen (rys))

ENGERIX -B PRODUCT INFORMATION (Hepatitis B surface antigen (rys)) ENGERIX -B PRODUCT INFORMATION (Hepatitis B surface antigen (rys)) NAME OF THE MEDICINE ENGERIX-B Hepatitis B surface antigen recombinant (yeast) vaccine DESCRIPTION Suspension for injection. 10 µg dose

More information

ABC/3TC/ZDV ABC PBO/3TC/ZDV

ABC/3TC/ZDV ABC PBO/3TC/ZDV The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: XX/XXXX

See 17 for PATIENT COUNSELING INFORMATION. Revised: XX/XXXX HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TWINRIX safely and effectively. See full prescribing information for TWINRIX. TWINRIX [Hepatitis

More information

TRANSPARENCY COMMITTEE OPINION. 19 May 2010

TRANSPARENCY COMMITTEE OPINION. 19 May 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 May 2010 HAVRIX NOURRISSONS ET ENFANTS 720 U/0.5 ml, suspension for injection in prefilled syringe. Inactivated,

More information

This is the cached copy of Submit search Go. Home Find Studies. Browse Medical Conditions

This is the cached copy of   Submit search Go. Home Find Studies. Browse Medical Conditions Pagina 1 di 7 This is the cached copy of http://www.gsk-clinicalstudyregister.com/study/217744/031. Search text Search Submit search Go Home Find Studies Browse Medical Conditions Browse Compound Names

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:

GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title: GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: 111426 (EPI-ROTA-111426) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK)

More information